pharmaphorum Podcast

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid biopsies should become standard in oncology. Newland explains how current US FDA-approved tests can detect some types of advanced cancers, predict prognosis, and help healthcare providers make treatment decisions. And importantly, Newland describes how live cell liquid biopsies are a UK-developed technology that aligns with national efforts to modernise cancer diagnostics, as well as potentially reduce healthcare costs by minimising ineffective treatments. You can listen to episode 238 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

It goes without saying that drug pricing and accessibility in the United States are complex indeed. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to transform the healthcare industry, about these intricacies. Patel discusses some intriguing stories about crafting innovative solutions for employers, revitalising struggling independent pharmacies, and implementing hybrid care models that can make healthcare more attainable for everyone. The conversation touches upon how biosimilars driving pharmaceutical innovation and reducing health costs, the role of telemedicine, also. You can listen to episode 237 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Gefion is Denmark’s first AI supercomputer, named after a goddess in Danish mythology. It is operated by the Danish Centre for AI Innovation (DCAI), a company established with funding from the Novo Nordisk Foundation, the world’s wealthiest charitable foundation, as well as the Export and Investment Fund of Denmark. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president and head of research, for a conversation on AI – specifically, Lundbeck’s agreement with the DCAI to run and operate Gefion – and accelerating drug discovery and development within the neurological and psychiatric field. You can listen to episode 236 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Illumina innovative sequencing and array technologies are fuelling groundbreaking advancements in life sciences research, translational and consumer genomics, and molecular diagnostics. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Markus Vossman, Germany general manager at Illumina, about innovative genomic applications and projects in the region. Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a large-scale national pilot project aiming to evaluate the utility of genomic sequencing for patients with advanced cancer and rare diseases. You can listen to episode 235 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

The FDA recently announced that it will begin offering faster drug reviews to certain medicines, reducing the drug review process from approximately ten months to one or two months. This news follows a series of rapid changes from the FDA since the Trump administration took office. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a healthcare personalization platform helping insurers, health systems, and pharmacies deliver precision nudges to move patients into action. Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective, as well as how regulatory changes, such as fast-tracking drug approvals as seen with the FDA lately, can impact patient perception. You can listen to episode 234 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.